The participating funds pursue the goal of concluding discount contracts for the active ingredient bevacizumab with all suitable pharmaceutical companies in accordance with Section 130a (8) SGB V. The contract is concluded as part of the open house biological process of the participating funds:

Individual negotiations on the content of the contract are not conducted; uniform conditions apply. The participating cash registers do not guarantee exclusivity for individual contractual partners. The contract runs for a maximum of 24 months starting on August 1st, 2020. The contract ends on July 31, 2022 at the latest, regardless of the date of conclusion of the contract. All further information can be found in the participation and contract documents.

It is possible to join this open house biological process at any time within the contract period.

A contract is concluded with all pharmaceutical companies that meet the requirements of Annex 4 to the contract (self-declaration for approval and for the company) and who confirm this in electronic form in accordance with § 126a BGB.

This announcement does not apply to the award of a public contract within the meaning of the Public Procurement Directive (2014/24 / EC) or the antitrust law. In the interest of the broadest possible information for interested pharmaceutical companies, this announcement is made in the supplement to the Official Journal of the European Union. The process name "Open Procedure" used in the context of the present notice text in accordance with section IV.1.1) and the specification of the award criteria in accordance with section II.2.5) are due to the requirements of the notice form and have no further significance. Hereby and with the use of the medium "TED "is not subject to any submission to public procurement regulations, the validity of which is not prescribed by law or procurement regulations.